Starpharma (ASX:SPL) share price surges higher on COVID product update

The Starpharma Holdings Limited (ASX:SPL) share price is surging higher on Thursday after releasing an update on its Viraleze product…

| More on:
A woman kicks a giant COVID-19 molecule, indicating positive share price movement for biotech companies

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Starpharma Holdings Limited (ASX: SPL) share price has been a strong performer on Thursday.

At the time of writing, the dendrimer products developer's shares are up 6% to $1.89.

Why is the Starpharma share price racing higher?

Investors have been buying Starpharma's shares following the release of an update on its Viraleze antiviral nasal spray.

According to the release, the Viraleze antiviral nasal spray is now available for purchase by consumers in Europe via the company's webstore.

This follows the recent launch of Viraleze in the United Kingdom through LloydsPharmacy's 1,400 stores and online business. It is also expected to be available via independent United Kingdom pharmacies later this month.

What is Viraleze?

Viraleze is a broad spectrum antiviral nasal spray that contains astodrimer sodium (SPL7013). This is virucidal, irreversibly inactivating >99.9% of coronavirus/SARS-CoV-2 within one minute.

These antiviral studies were conducted at the renowned Scripps Research Institute in the United States and a number of other specialist virology laboratories.

It isn't just multiple strains of COVID-19 that Viraleze has been demonstrated to have potent antiviral activity. It also has been found to have potent antiviral activity against RSV (respiratory syncytial virus), MERS, and SARS.

Management notes that the antiviral active in Viraleze works by irreversibly blocking coronavirus SARS-CoV-2 'spike' proteins from binding to human airway cells. This forms a physical barrier to respiratory viruses in the nasal cavity and has multiple unique advantages. One of these is its ability to inactivate the virus either before or after exposure.

Starpharma's CEO, Dr Jackie Fairley, commented: "We are delighted to be rolling out Viraleze in Europe following the UK launch. The product has been very well received in the UK, and we hope that Viraleze will provide European consumers with added peace of mind."

"In addition to making Viraleze available direct to consumers in Europe via www.viraleze.co, commercial discussions for distribution continue in parallel. Starpharma is actively engaged in discussions with a variety of organisations in the region, including sporting teams, which have expressed interest in Viraleze," she concluded.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing end to the trading week for investors this Friday.

Read more »

A young boy points and smiles as he eats fried chicken.
Share Gainers

3 ASX All Ords shares smashing the benchmark this week

Investors are sending these three ASX All Ords shares rocketing 18% to more than 29% this week. But why?

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why Alliance Aviation, BHP, Boss Energy, and Orthocell shares are racing higher

These shares are ending the week on a positive note. But why?

Read more »

Man with backpack spreading his arms out and soaking in the sun.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing session for investors today.

Read more »

Hands reaching high for a trophy with a sunset in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a nervous hump day session for ASX investors today.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Why Collins Foods, DroneShield, Star Entertainment, and Virgin Australia shares are charging higher

These shares are having a good time on hump day. But why?

Read more »

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors enjoyed a strong recovery day this Tuesday.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Share Gainers

CBA shares hit another all-time high. Can they surpass $200 in 2025?

CBA shares have a tailwind pushing up their price that has nothing directly to do with the bank's business performance.

Read more »